StockData

Concord Medical Services vs Starling Oncology

CCM and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CCM and STLN compare

Starling Oncology grew revenue faster over the last twelve months (34.6% versus 19.9% for Concord Medical Services).

Starling Oncology keeps more of each dollar of sales as profit, with a net margin of −5.7% compared with −20.2% at Concord Medical Services.

Starling Oncology scores higher on the StockData Score (8 against 3 for Concord Medical Services), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCCMSTLN
Size and price
Market cap–$357M
Share price$3.62$3.50
Change, 1 year−24.4%2.0%
Change, 5 years−85.3%−54.6%
Beta (5Y)0.321.69
Employees610641
StockData Score
Total score38 (better)
Valuation score01 (better)
Growth score23 (better)
Performance score12 (better)
Health score02 (better)
Dividend score00
Valuation
P/S–0.6×
P/FCF–18.9×
FCF yield–5.3%
Growth
Revenue growth (TTM)19.9%34.6% (better)
Revenue growth, 5Y average15.6%21.8% (better)
Profitability
Gross margin5.6%–
Operating margin−56.8%−3.4% (better)
Net margin−20.2%−5.7% (better)
FCF margin−56.1%3.0% (better)
Return on invested capital−19.3% (better)−96.2%
Financial health
Interest coverage−1.7× (better)−2.0×
Current ratio0.481.11 (better)
Altman Z-score–1.74
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.03%43.4%
Held by insiders0.83%56.6%
Insider net buying, 12 months–−$11.1M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.